Livzon Pharmaceutical Group Inc. provided earnings guidance for the year ended December 31, 2016. For the year, the company’s net profit attributable to the shareholders of the company expected to increase by approximately 20% to 30% as compared to the corresponding period last year and basic earnings per share of approximately RMB 1.94 to RMB 2.11. The annual results of the company for the year 2016 increased as compared to the corresponding period last year, which is mainly attributable to: The effective progress in the expansion and development of the distribution channel of preparation products have led to a steady growth in the prescription medicine business of Company. The profit of Shenqi Fuzheng Injection(one of major products) has been increasing steadily, while the profit of uprising products has been growing rapidly; the profitability of bulk medicine business has achieved a significant and continuous improvement.